These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 16508606)

  • 21. Antipsoriatic biologic agents for the treatment of atopic dermatitis.
    Heymann WR
    J Am Acad Dermatol; 2007 May; 56(5):854-5. PubMed ID: 17437891
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of psoriatic arthritis and recalcitrant skin disease with combination therapy.
    Hamilton TK
    J Drugs Dermatol; 2008 Nov; 7(11):1089-93. PubMed ID: 19110745
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Keratinocyte overexpression of IL-17C promotes psoriasiform skin inflammation.
    Johnston A; Fritz Y; Dawes SM; Diaconu D; Al-Attar PM; Guzman AM; Chen CS; Fu W; Gudjonsson JE; McCormick TS; Ward NL
    J Immunol; 2013 Mar; 190(5):2252-62. PubMed ID: 23359500
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term management of erythrodermic psoriasis with anti-TNF agents.
    Romero-Maté A; García-Donoso C; Martinez-Morán C; Hernández-Núñez A; Borbujo J
    Dermatol Online J; 2010 Jun; 16(6):15. PubMed ID: 20579470
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biologic therapy for psoriasis--the first wave: infliximab, etanercept, efalizumab, and alefacept.
    Weinberg JM; Saini R; Tutrone WD
    J Drugs Dermatol; 2002 Dec; 1(3):303-10. PubMed ID: 12851990
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Psoriasis: Is ustekinumab superior to etanercept for psoriasis?
    Kuhn A; Luger TA
    Nat Rev Rheumatol; 2010 Sep; 6(9):500-1. PubMed ID: 20808304
    [No Abstract]   [Full Text] [Related]  

  • 27. [Therapeutic application of TNF-alpha inhibitors infliximab and etanercept in inflammatory skin disorders].
    Jacobi A; Manger B; Schuler G; Hertl M
    J Dtsch Dermatol Ges; 2003 Apr; 1(4):259-72. PubMed ID: 16285480
    [TBL] [Abstract][Full Text] [Related]  

  • 28. TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques.
    Gottlieb AB; Chamian F; Masud S; Cardinale I; Abello MV; Lowes MA; Chen F; Magliocco M; Krueger JG
    J Immunol; 2005 Aug; 175(4):2721-9. PubMed ID: 16081850
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [A case of granulomatous rosacea coinciding with the use of etanercept: no relapse with infliximab].
    Winter UM; Treudler R; Paasch U; Sticherling M; Simon JC
    Hautarzt; 2008 Sep; 59(9):724-7. PubMed ID: 18465064
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biological agents in the treatment of psoriasis.
    Tzu J; Krulig E; Cardenas V; Kerdel FA
    G Ital Dermatol Venereol; 2008 Oct; 143(5):315-27. PubMed ID: 18833073
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Survival rate of antitumour necrosis factor-α treatments for psoriasis in routine dermatological practice: a multicentre observational study.
    Esposito M; Gisondi P; Cassano N; Ferrucci G; Del Giglio M; Loconsole F; Giunta A; Vena GA; Chimenti S; Girolomoni G
    Br J Dermatol; 2013 Sep; 169(3):666-72. PubMed ID: 23647206
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Endothelial dysfunction and the effects of TNF inhibitors on the endothelium in psoriasis and psoriatic arthritis: a systematic review.
    Brezinski EA; Follansbee MR; Armstrong EJ; Armstrong AW
    Curr Pharm Des; 2014; 20(4):513-28. PubMed ID: 23565632
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of tumor necrosis factor inhibitors in acute generalized pustular psoriasis.
    Viguier M; Aubin F; Delaporte E; Pagès C; Paul C; Beylot-Barry M; Goujon C; Rybojad M; Bachelez H;
    Arch Dermatol; 2012 Dec; 148(12):1423-5. PubMed ID: 23247492
    [No Abstract]   [Full Text] [Related]  

  • 34. Experience with biologics for psoriasis in daily practice: switching is worth a try.
    Lecluse LL; de Groot M; Bos JD; Spuls PI
    Br J Dermatol; 2009 Oct; 161(4):948-51. PubMed ID: 19663876
    [No Abstract]   [Full Text] [Related]  

  • 35. An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis.
    Weinberg JM
    Clin Ther; 2003 Oct; 25(10):2487-505. PubMed ID: 14667953
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adalimumab vs. etanercept in psoriasis.
    Downs AM
    Clin Exp Dermatol; 2007 Sep; 32(5):593. PubMed ID: 17692064
    [No Abstract]   [Full Text] [Related]  

  • 37. Efficacy of etanercept in psoriatic patients previously treated with infliximab.
    Pitarch G; Sánchez-Carazo JL; Mahiques L; Oliver V
    Dermatology; 2008; 216(4):312-6. PubMed ID: 18230978
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Successful treatment of hidradenitis suppurativa with infliximab in a patient who failed to respond to etanercept.
    Poulin Y
    J Cutan Med Surg; 2009; 13(4):221-5. PubMed ID: 19706231
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The role of biological drugs in the treatment of psoriasis, results from 9 randomized placebo-controlled trials].
    Kemény L; Brodszky V; Kárpáti K; Gulácsi L
    Orv Hetil; 2006 May; 147(21):981-90. PubMed ID: 16812973
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Switching to adalimumab in patients with moderate to severe psoriasis who have failed on etanercept: a retrospective case cohort study.
    Woolf RT; Smith CH; Robertson K; Barker JN
    Br J Dermatol; 2010 Oct; 163(4):889-92. PubMed ID: 20854408
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.